drugset / Trial / NCT07545382
Rivastigmine as an Antidote for Clozapine and Other Anticholinergic-Induced CNS Depression and Delirium: A Study of 100 Cases
NaSingle-groupOpen-labelTreatment
Summary
This study aims to evaluate the clinical efficacy and safety of rivastigmine in reversing the full spectrum of anticholinergic delirium including hypoactive delirium which is presented with CNS depression and hyperactive or agitated delirium. The study was conducted on 100 patients at the Poison Control Center of Alexandria University Main Hospital. The primary objective is to assess the effectiveness of rivastigmine in restoring consciousness and improving cognitive function in patients presenting with delirium and depressed mental status using GCS and RASS score.
Timeline
- Start
- 2025-12-08
- Primary completion
- 2026-04-15
- Completion
- 2026-04-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivastigmine | Small molecule | 6 mg | Oral |
| Subject | Rivastigmine | Small molecule | 9.5 mg | Oral |